Talaris Therapeutics falls after patient dies in late-stage trial

Tourmaline Bio

20/10/2022 13:11

** Talaris Therapeutics' shares  TALS.O  fall 25% to $1.81
premarket
    ** Co said Tuesday a patient died in a late-stage study on
cell therapy for kidney transplant recipients  urn:newsml:reuters.com:*:nGNX2285Cq
    ** Says trial was temporarily halted before independent
panel allowed resumption after a review
    ** Says informed FDA of the situation
    ** 2 of 4 brokerages rate the stock "buy" or higher, 2
"hold"; their median PT is $13.50
    ** Up to Wednesday's close, stock had fallen 84% YTD
 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))